BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 22482453)

  • 1. Tau and tauopathies.
    Lee G; Leugers CJ
    Prog Mol Biol Transl Sci; 2012; 107():263-93. PubMed ID: 22482453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of the tauopathies.
    Goedert M; Spillantini MG
    J Mol Neurosci; 2011 Nov; 45(3):425-31. PubMed ID: 21785996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.
    Yotsumoto K; Saito T; Asada A; Oikawa T; Kimura T; Uchida C; Ishiguro K; Uchida T; Hasegawa M; Hisanaga SI
    J Biol Chem; 2009 Jun; 284(25):16840-16847. PubMed ID: 19401603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Important neuronal toxicity of microtubule-bound Tau in vivo in Drosophila.
    Talmat-Amar Y; Arribat Y; Redt-Clouet C; Feuillette S; Bougé AL; Lecourtois M; Parmentier ML
    Hum Mol Genet; 2011 Oct; 20(19):3738-45. PubMed ID: 21705366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The microtubule-associated protein tau in neurodegenerative diseases. Tauopathies].
    Sánchez MP; Alvarez-Tallada V; Avila J
    Rev Neurol; 2001 Jul 16-31; 33(2):169-77. PubMed ID: 11562878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
    Venkatramani A; Panda D
    Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?
    Fernandez-Gomez F; Tran H; Dhaenens CM; Caillet-Boudin ML; Schraen-Maschke S; Blum D; Sablonnière B; Buée-Scherrer V; Buee L; Sergeant N
    Adv Exp Med Biol; 2019; 1184():207-216. PubMed ID: 32096040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau protein in familial and sporadic diseases.
    Yancopoulou D; Spillantini MG
    Neuromolecular Med; 2003; 4(1-2):37-48. PubMed ID: 14528051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?
    Alavi Naini SM; Soussi-Yanicostas N
    Oxid Med Cell Longev; 2015; 2015():151979. PubMed ID: 26576216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.
    Liu K; Liu Y; Li L; Qin P; Iqbal J; Deng Y; Qing H
    Biochim Biophys Acta; 2016 Feb; 1862(2):192-201. PubMed ID: 26655600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy.
    Eckermann K; Mocanu MM; Khlistunova I; Biernat J; Nissen A; Hofmann A; Schönig K; Bujard H; Haemisch A; Mandelkow E; Zhou L; Rune G; Mandelkow EM
    J Biol Chem; 2007 Oct; 282(43):31755-65. PubMed ID: 17716969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission of tauopathy strains is independent of their isoform composition.
    He Z; McBride JD; Xu H; Changolkar L; Kim SJ; Zhang B; Narasimhan S; Gibbons GS; Guo JL; Kozak M; Schellenberg GD; Trojanowski JQ; Lee VM
    Nat Commun; 2020 Jan; 11(1):7. PubMed ID: 31911587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontotemporal dementia with tau pathology.
    Gasparini L; Terni B; Spillantini MG
    Neurodegener Dis; 2007; 4(2-3):236-53. PubMed ID: 17596718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
    Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
    J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration.
    Higuchi M; Ishihara T; Zhang B; Hong M; Andreadis A; Trojanowski J; Lee VM
    Neuron; 2002 Aug; 35(3):433-46. PubMed ID: 12165467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tauopathies.
    Hernández F; Avila J
    Cell Mol Life Sci; 2007 Sep; 64(17):2219-33. PubMed ID: 17604998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau and tauopathies.
    Arendt T; Stieler JT; Holzer M
    Brain Res Bull; 2016 Sep; 126(Pt 3):238-292. PubMed ID: 27615390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.